Use of a TAMM41 activator, drynachromoside B, in improving mitochondrial dysfunction
By activating the TAMM41 enzyme through Drynachromoside B and promoting cardiolipin synthesis, the lack of molecular specificity for mitochondrial dysfunction in existing technologies has been addressed, enabling multidimensional mitochondrial function recovery.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- XUZHOU MEDICAL UNIVERSITY
- Filing Date
- 2026-05-27
- Publication Date
- 2026-07-17
AI Technical Summary
Current treatments for mitochondrial dysfunction mainly involve scavenging reactive oxygen species or stabilizing cardiolipin, but these methods lack molecular specificity and are difficult to achieve lasting and stable recovery.
Drynachromoside B was used as a TAMM41 activator. By binding to TAMM41, its enzyme activity was activated, promoting the production of CDP-diacylglycerol, restoring cardiolipin synthesis, and maintaining mitochondrial membrane structure and respiratory chain function.
It significantly restores mitochondrial function at both cellular and isolated mitochondrial levels, reduces membrane permeability, enhances membrane potential and respiratory chain electron transport efficiency, reduces reactive oxygen species production, and achieves multidimensional mitochondrial protection.
Smart Images
Figure CN122398836A_ABST